Vicky Hsu - Concepedia

Author

Vicky Hsu

United States Food and Drug Administration

Also Known As

V Hsu, Vicky Hsu

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Center for Drug Evaluation and Research

About

Vicky Hsu is an author at United States Food and Drug Administration specializing in medicine, pharmacology, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	753
2	Biochemistry	3	3	241
3	Engineering	1	1	113
4	Health Sciences	1	1	133
5	Biomedical Engineering	1	1	113

Vicky Hsu

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK Christian Wagner, Ping Zhao, Y. Pan, CPT Pharmacometrics & Systems Pharmacology	2015	267
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma Elaine Chang, Chana Weinstock, Lijun Zhang, Clinical Cancer Research Peripheral NeuropathyUrologySeattle GeneticsGenitourinary CancerMedicine	2020	173
Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug Administration Christian Wagner, Yuzhuo Pan, Vicky Hsu, Clinical Pharmacokinetics Cytochrome P450 InhibitorsPhysiologically Based PharmacokineticsPharmacokinetic ModelingBiochemistrySubstrate Drugs	2014	143
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation Kelly J. Norsworthy, Lola Luo, Vicky Hsu, Clinical Cancer Research Differentiation SyndromeMixed-phenotype Acute LeukemiaPharmacotherapyTransfusion DependenceMyeloid Neoplasia	2019	133
Advancing Predictions of Tissue and Intracellular Drug Concentrations Using <i>In Vitro</i>, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches Yingying Guo, Xiaoyan Chu, Neil Parrott, Clinical Pharmacology & Therapeutics EngineeringBiomedical EngineeringPharmacokinetic Modeling ApproachesPhysiologically-based Pharmacokinetic ModelingPharmacodynamic Modeling	2018	113
Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA Christian Wagner, Yuzhuo Pan, Vicky Hsu, Clinical Pharmacokinetics Physiologically Based PharmacokineticsPharmacokinetic ModelingCyp3a InducersPbpk SubmissionsPharmacology	2015	93
PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters C‐H Hsueh, Vicky Hsu, Ping Zhao, Clinical Pharmacology & Therapeutics Renal FunctionPharmacokinetic ModelingBiochemistryHealthy SubjectsMedicine	2017	80
The Prevalence of Major Depressive Disorder and Low Self-Esteem in Medical Inpatients Peter H. Silverstone, Tania Lemay, Jasen Elliott, The Canadian Journal of Psychiatry	1996	31
Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug–Drug Interactions Involving Enzyme Modulation Chia‐Hsiang Hsueh, Vicky Hsu, Yuzhuo Pan, Clinical Pharmacokinetics Systems PharmacologyMolecular PharmacologyPhysiologically Based PharmacokineticsPharmacokinetic ModelingPharmacodynamics	2018	18

Page 1